GlassScriptPhysician profile
Nathan A Cobb
NPI 1720648157
$1,297.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.55 · 2022: $259 · 2023: $667 · 2024: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $245.07 | 2022-2024 | |
| Novo Nordisk INC | $212.15 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $167.83 | 2022-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $128.12 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $115.05 | 2023 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $86.06 | 2022-2024 | Trintellix |
| Glaxosmithkline, LLC. | $76.07 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.93 | 2022-2023 | Tradjenta, Jardiance |
| Viiv Healthcare Company | $47.13 | 2024 | Apretude |
| Axsome Therapeutics, INC. | $28.05 | 2023 | Auvelity |
| Amgen INC. | $27.42 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $21.11 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $19.55 | 2020 | |
| Astellas Pharma US INC | $19.21 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $19.10 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.51 | 2022 | |
| Merck Sharp & Dohme LLC | $16.34 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.